Generics - Actavis, Pharmaceutical

Filter

Current filters:

ActavisPharmaceutical

Popular Filters

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

Avanir Pharma settles Nuedexta patent litigation with Actavis

03-09-2013

USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) says that it has entered into a settlement agreement…

ActavisAvanir PharmaceuticalsGenericsLegalNeurologicalNorth AmericaNuedextaPatentsPharmaceutical

FTC submits proposed Amicus Brief on "No-Authorized-Generic" commitments in drug patent settlements

21-08-2013

The US Federal Trade Commission has asked the US District Court for the District of New Jersey to accept…

ActavisEffexor XRGenericsLegalNorth AmericaPfizerPharmaceuticalTeva Pharmaceutical IndustriesWyeth

Actavis debuts new formulations of Fioricet

30-07-2013

US generics major Actavis (NYSE: ACT) has launched new formulations of Fioricet (butalbital, acetaminophen…

AcetaminophenActavisFioricetFioricet with CodeineGenericsMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent

19-06-2013

USA-based Actavis (NYSE: ACT), itself predominantly a generic drug marketer, and Japan's Kissei Pharmaceutical…

ActavisGenericsHetero GroupMen's HealthNorth AmericaNovartisPatentsPharmaceuticalRapaflo CapsulesSandoz

US Appeals Court puts temporary stop on sales of generics of AstraZeneca's Pulmicort Respules

27-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last Friday (May 24) that the US Court of Appeals…

ActavisAstraZenecaGenericsLegalMarkets & MarketingNorth AmericaPharmaceuticalPulmicort RespulesRespiratory and Pulmonary

Actavis confirms plan to acquire Warner Chilcott, in $8.5 billion deal

20-05-2013

US generics major Actavis (NYSE: ACT) revealed today (May 20) that it has entered into a definitive agreement…

ActavisGenericsMergers & AcquisitionsPharmaceuticalWarner ChilcottWomen's Health

Actavis and Warner Chilcott leap on merger talks; possible bid for Adcock Ingram

13-05-2013

US generics major Actavis NYSE: ACT) confirmed on Friday (May 10) that it has entered into early stage…

ActavisAdcock IngramFinancialGenericsMergers & AcquisitionsPharmaceuticalWarner Chilcott

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Proposed sourcing on Supreme Court reverse payment drug patent case; lawyers' views

06-05-2013

Within the next several weeks, the US Supreme Court is expected to hand down a ruling in an important…

ActavisGenericsLegalNorth AmericaPatentsPharmaceutical

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion

21-12-2012

The US District Judge Reggie Walton, of the District Court for the District of Columbia, has dismissed…

ActavisComtanEndo PharmaceuticalsGenericsImpax LaboratoriesLegalMylan LaboratoriesNeurologicalNorth AmericaOpana ERPharmaceutical

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Shire to face generic competition for Adderall XR from Actavis

25-06-2012

Shares in UK drugmaker Shire (LSE: SHP) fell around 9% to £17.82 in early trading this morning,…

ActavisAdderall XRGenericsNeurologicalNorth AmericaPharmaceuticalRegulationShireWatson Pharmaceuticals

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Depomed files patent infringement suits relating to Gralise

05-03-2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

New Actavis/Bioton alliance aims to shake up diabetes market

31-01-2012

Icelandic generics drugmaker Actavis and Poland’s Bioton (WSE: BIO) have formed a joint venture…

ActavisBiotonDiabetesGenericsMarkets & MarketingMergers & AcquisitionsPharmaceutical

Back to top